Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration

MARIKO MIYAZAWA, MASANORI YASUDA, MASAKI MIYAZAWA, NAOKI OGANE, TOMOMI KATOH, MITSUTAKE YANO, TAKESHI HIRASAWA, MIKIO MIKAMI and HITOSHI ISHIMOTO
Anticancer Research December 2020, 40 (12) 6791-6798; DOI: https://doi.org/10.21873/anticanres.14702
MARIKO MIYAZAWA
1Department of Obstetrics and Gynaecology, Tokai University School of Medicine, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASANORI YASUDA
2Department of Pathology, Saitama Medical University International Medical Centre, Saitama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m_yasuda@saitama-med.ac.jp
MASAKI MIYAZAWA
1Department of Obstetrics and Gynaecology, Tokai University School of Medicine, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOKI OGANE
3Department of Pathology, Kanagawa Prefectural Ashigarakami Hospital, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOMI KATOH
2Department of Pathology, Saitama Medical University International Medical Centre, Saitama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MITSUTAKE YANO
2Department of Pathology, Saitama Medical University International Medical Centre, Saitama, Japan;
4Department of Obstetrics and Gynaecology, Oita University Faculty of Medicine, Oita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI HIRASAWA
1Department of Obstetrics and Gynaecology, Tokai University School of Medicine, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MIKIO MIKAMI
1Department of Obstetrics and Gynaecology, Tokai University School of Medicine, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HITOSHI ISHIMOTO
1Department of Obstetrics and Gynaecology, Tokai University School of Medicine, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Advanced ovarian clear-cell carcinoma (CCC) fails to respond to standard chemotherapy, and has a poor prognosis. Since hypoxia-inducible factor-1 (HIF-1) stimulates various genes involved in cancer, we aimed to examine the efficacy of silibinin, an active component of milk thistle belonging to Asteraceae, in suppressing HIF-1 activity, and elucidate the underlying mechanism in human CCC cell lines. Materials and Methods: Human ovarian CCC cell lines HAC-2, OVISE, and RMG-1 were treated with 500 μM silibinin for 4 h under normoxic and hypoxic conditions. Using DNA microarray, we analysed genes whose expression modulated more than 2-fold in response to hypoxia, whereas HIF-1α expression was measured using ELISA. Results: Silibinin treatment decreased HIF-1α protein in all cell lines, and eIF4E2 and RPS6 mRNA in HAC-2 and RMG-1 cells. Conclusion: Silibinin suppressed HIF-1α protein under hypoxic conditions in CCC cell lines and could be a potential anti-cancer drug.

Key Words:
  • HIF-1α
  • silibinin
  • eIF4E
  • RPS6
  • ovarian clear-cell carcinoma

Clear-cell carcinoma (CCC) is the second most common histological type of cancer in Japan, accounting for 30% of all ovarian carcinomas (1, 2). In comparison with serous carcinoma (3), which is the most frequent carcinoma type, advanced cases of CCC have an unfavourable prognosis due to poor response to standard anti-cancer chemotherapy comprising of paclitaxel and carboplatin (4).

Currently, novel strategies, using poly ADP-ribose polymerase (PARP) inhibitor and immune-checkpoint inhibitors, are being gradually introduced (5, 6). However, these agents are mainly targeted towards serous carcinoma, instead of CCC. Hypoxia is a classical condition accompanying cancer growth. In hypoxic environments, hypoxia-inducible factor-1 (HIF-1) plays a pivotal role as a transcription factor as well as a putative anti-cancer therapeutic agent (7-12). However, down-regulation of HIF-1 is challenging, since it is also essential for maintaining systemic homeostasis. Previously, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, was assessed as a therapeutic agent for ovarian cancer in a phase II trial. Currently, everolimus is applicable as a therapeutic alternative in renal cancer (13, 14), neuroendocrine neoplasms (15-17), and breast cancer (18-21); however, its applicability in ovarian cancer remains unknown (3, 22).

Silibinin is a component of silymarin, a standardised extract of the milk thistle seeds (23-25). It was originally used in European folk medicine to treat liver dysfunction; it also exhibited anti-cancer activity in the ovarian endometrioid and serous carcinoma cell lines via extracellular signal-regulated kinase and Akt (26). Studies have suggested that silibinin has multiple targets in the cell (27, 28). In the SEC cell line, the combined use of silibinin and paclitaxel showed significant suppression of cell proliferation and significant up-regulation of tumour suppressor genes P53 and P21, and is more effective in treating ovarian cancer. This was verified in a study on drug resistance caused by long-term use of paclitaxel (29). A study showed that cisplatin and taxol could restore the sensitivity of the combinatorial administration of cisplatin and taxol in drug-resistant human ovarian cancer cells and reduce drug-induced hepatotoxicity in drug-resistant ovarian endometrioid carcinoma cell lines (30). Thus, silibinin may be employed as a part of combinatorial therapies against ovarian cancer.

Hence, our study aimed to explore the effect of silibinin on suppressing CCC growth, and evaluate its efficacy as a potent anti-cancer drug.

Materials and Methods

Cell lines and reagents. The human ovarian CCC cell lines HAC-2, OVISE, and RMG-1 were kindly provided by Professor Kazunari Kiguchi, Department of Obstetrics and Gynaecology, St. Marianna University School of Medicine (Kanagawa, Japan). The cells were cultured in RPMI-1640 medium (R8758, Sigma-Aldrich, Tokyo, Japan) supplemented with 10% foetal bovine serum (FBS) and 1% penicillin-streptomycin. HeLa, a human cervical adenosquamous cell carcinoma cell line, was provided by the Support Centre for Medical Research and Education, Isehara Research Promotion Division, Tokai University. HeLa cells were cultured in minimum essential medium (M4655, Sigma-Aldrich) supplemented with 10% FBS and 1% penicillin-streptomycin. All cells were cultured at 37°C at 5% CO2 in a humidified atmosphere.

Silibinin (1006211), purchased from Cayman Chemical (Ann Arbor, MI, USA), was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 1.0×106 μM to make the stock solution. Deferoxamine mesylate (DFO) (5764) was purchased from TOCRIS (Bristol, England), and dissolved in DMSO to a concentration of 100 mM to prepare the stock solution.

Lactate dehydrogenase (LDH) activity-based cytotoxicity assay. To evaluate the cytotoxicity of silibinin, LDH released from the lysed cells was quantitatively measured using the LDH Cytotoxicity Assay Kit (601170/Cayman Chemical) according to the manufacturer’s instructions. All the cell lines were treated with 500 μM silibinin, followed by 4 h incubation at 37°C in a 5% CO2 incubator. The value of LDH obtained by subtracting the blank (medium only) was used for the calculation: (%)=experimental LDH release/maximum LDH release ×100 (maximum LDH release: 45 min before the end of culture, 0.1% Triton X-100 (X100PC-5X5ML, Sigma-Aldrich).

HIF-1α cell-based ELISA. All the cell lines were treated with 500 μM silibinin, and cultured in a humidified atmosphere at 5% CO2 (normal atmospheric condition) for 0 h or 4 h, as well as hypoxic conditions (2% oxygen concentration). As a positive control, the cells were cultured for 4 h in a culture medium containing 200 μM DFO to induce HIF-1α expression. After culture, the HIF-1α expression level was compared by luminescence intensity (RFU), using the HIF-1α Cell-Based ELISA Kit (CBA-281, CELL BIOLABS, San Diego, CA, USA), according to the assay protocol.

RNA extraction and quantification. Total cellular RNA was isolated from the cells using the RNeasy Mini RNA isolation kit (74104, Qiagen, Hilden, Germany). Total RNA was eluted from RNeasy Mini columns using 30 μL RNase-free water. RNA quantity was estimated using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific NanoDrop Technologies, Wilmington, DE, USA), and RNA integrity was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

DNA microarray analysis. Total RNA from the 500 μM silibinin-treated and untreated (only DMSO-treated) HAC-2 and RMG-1 cells was extracted as mentioned above. Genes that showed more than two-fold fluctuation after silibinin treatment, as assessed by performing SurePrint G3 Human GE Microarray 8x60K Ver. 3.0 (G4858A # 72363, Agilent Technologies), compared to the untreated group, were considered to be modulated. In the present study, we emphasised on the HIF-related factors.

Statistical analysis. Statistical analyses of the data were performed using IBM SPSS Statistics version 25. Data are presented as the mean±SD from three independent experiments, except for DNA microarray, in which two independent experiments were performed. Data were analysed by the Student’s t-test or one-way analysis of variance (ANOVA), and results with p<0.05 were considered statistically significant.

Results

LDH release ratio. The LDH release ratios of HAC-2 and RMG-1 cells were 10% or less of those of the control (untreated cells). However, the amount of LDH released was significantly increased (p=0.0029) in the HeLa cells of silibinin-treated group (Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Evaluation of silibinin cytotoxicity. Each cell line was treated with silibinin (500 μM) and incubated for 4 h under normal atmospheric conditions and hypoxic condition, at oxygen concentration of 2%; the cell-culture supernatant was used to measure the LDH concentration. In HAC-2, OVISE, and RMG-1 cells, LDH release was approximately 10% of that released by the control; however, in HeLa cells, LDH release was significantly higher in the silibinin-treated group. *1; p=0.0004, *2; p=0.0029.

HIF-1α protein expression. HIF-1α protein expression was induced under hypoxic conditions (Figure 2); however, its level did not increase in the untreated HAC-2 cells. In HeLa cells, hypoxia induced HIF-1α protein expression at the same level as by DFO stimulation (data not shown), but the induction of HIF-1α expression in HAC-2 and OVISE cells was mild under 4-h hypoxic conditions. In RMG-1 cells, the HIF-1α expression level was not affected by the 4-h hypoxic condition. However, HIF-1α protein level was significantly reduced in HAC-2 and OVISE cells treated with silibinin under 4-h hypoxic conditions.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

HIF-1α protein expression in silibinin-treated cells. In RMG-1 cells, the expression level of HIF-1α protein was significantly down-regulated by silibinin treatment regardless of oxygen concentration. In HAC-2, OVISE, and HeLa cells, HIF-1α protein levels were significantly decreased by silibinin treatment under hypoxic conditions. *1; p=0.0018, *2; p=0.01, *3; p=0.0012, *4; p=0.00004, *5; p=0.0218.

DNA microarray analysis. Among the three cell lines, HAC-2 showed the highest basal level of HIF-1α protein expression; in RMG-1 cells, HIF-1α protein was significantly reduced in response to silibinin treatment, regardless of oxygenation conditions (Figure 2). Therefore, these cell lines were used for DNA microarray analysis to identify genes exhibiting ≥2-fold change in expression between the untreated/control group and the silibinin-treated group (Figure 3). The number of genes with more than 2-fold increase was 5111 in HAC-2, 8064 in RMG-1, and 2673 in both the cell lines (Figure 4A). Conversely, the number of genes with more than 2-fold decrease was 2600 in HAC-2, 1318 in RMG-1, and 883 in both the cell lines (Figure 4B).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Scatter plot of microarray data. A: HAC-2 cells; B: RMG-1 cells. Compared to that in the untreated group, the green line showed more than a 2-fold change in expression in response to silibinin treatment.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Number of genes with more than 2-fold change (FC) in expression as per microarray data. A: The number of genes with more than 2-fold increase in expression owing to silibinin treatment was 5111 in HAC-2, 8064 in RMG-1, and 2673 in both the cell lines. B: The number of genes that showed more than 2-fold decrease in expression owing to silibinin treatment was 2600 in HAC-2, 1318 in RMG-1, and 833 in both cell lines.

Interestingly, we observed that the expression of eukaryotic translation initiation factor 4E (eIF4E) and ribosomal protein S6e (RPS6), which promote HIF-1α mRNA translation, was significantly reduced in both cell types. In the silibinin-treated group, the expression of HIF-1α and other HIF-1-regulated genes was not altered by more than 2-fold (Figures 5 and 6). Furthermore, the expression of human PIK3R1 encoding phosphatidylinositol 3-kinase regulatory subunit alpha was reduced by approximately 2.8-fold. The HIF-1α-related genes that showed more than 2-fold increase in expression in response to silibinin treatment, were EPO, ERBB2, HK3, PDHA1, and RPS6KB1 (Figure 6).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Colouring of pathways by KEGG Mapper – Colour Pathway (HIF-1 signalling pathway). A: HAC-2 cells, B: RMG-1 cells. For the HIF-1 signalling pathway, the expression ratio of each gene in the microarray is displayed in different colours.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

HIF-1 signalling pathway-related genes that demonstrated more than 2-fold change in HAC-2 and RMG-1 cells. HAC-2 and RMG-1 cells shared 11 HIF-1 signalling pathway-related genes with more than a 2-fold change in expression upon silibinin treatment.

Discussion

Currently, approximately 70% of patients with ovarian cancer suffer from relapses after undergoing TC (Paclitaxel and Carboplatin) therapy, the proportion being even higher for patients at stages III and IV (31-33). In a previous study on epithelial ovarian cancer, we reported that HIF-1α expression and HIF-1 activation was significantly up-regulated in CCC (34). Therefore, this experimental study was based on the hypothesis that ovarian CCC may be suppressed by silibinin via its anti-cancer effect on HIF-1.

The amount of LDH released in response to silibinin treatment was 10% or less of that released by the control in all target cell lines, indicating that silibinin exerted negligible adverse effect on HIF-1α expression (Figure 1). Since the gene expression varies remarkably among the cell types, the function of silibinin may be influenced by the properties related to each cell type. Silibinin reportedly inhibits the Warburg effect in cancer cells through multiple mechanisms, including inhibiting HIF-1 activation (35, 36). It has also been reported to inhibit methionine and restore sensitivity to cisplatin and taxol in endometrioid cell lines, besides reducing drug-induced hepatotoxicity (37). Notably, its combination with paclitaxel to target incurable ovarian endometrioid carcinoma improves the outcome of primary ovarian cancer (38); a phase II clinical trial on prostate cancer was also recently conducted (39, 40).

Treatment with silibinin significantly attenuated the expression of eIF4E and RPS6 (Figures 3, 4, 5 and 6). EIF4E is a cap-binding protein that recognises the cap structure (5-cap’) at the 5’-end of mRNA. EIF4E binds to the cap structure along with the helicase eIF4A, and the large scaffolding protein eIF4G, thereby forming the ternary complex eIF4F to initiate cap-dependent translation (41). Since cap-dependent translation is involved in cell proliferation (26, 37, 38), its dysfunction would cause cancer cell development. In fact, several cancer cells overexpress eIF4E (26, 40), which in turn induces cancer cell development (34, 39). Phosphorylation of eIF4E-binding proteins (4E-BPs) by the PI3K/Akt/mTOR pathway, an HIF-1 activation pathway independent of oxygen concentration, hampers the eIF4E binding to 4E-BPs, and therefore, eIF4E binds to 4eIF4G, which is a scaffolding protein that bridges between eIF4E and 4E-BPs. Formation of eIF4F complex activates the cap-dependent translation (41). Down-regulation of these two genes by silibinin treatment can suppress the cap-dependent translation and ribosome biosynthesis, thereby exerting anti-cancer effects (Figure 5). A slight decrease in the PIK3R1 expression level was also observed (Figure 6). This gene codes for one of the regulatory subunits of class IA PI3K, and mutations in this gene play roles in various types of human solid tumours, including breast cancer as shown earlier (42).

Although no change was observed in the HIF-1α expression level (Figure 5), the amount of HIF-1α protein was significantly decreased (Figure 2). Moreover, HIF-1α synthesis was considerably suppressed despite HIF-1α overexpression. Silibinin is anticipated to be highly efficacious in suppressing HIF-1. Akt, as a factor influencing silibinin in vitro, is involved in cancers of breast, cervix, colon, lungs, ovary (serous carcinoma), and skin (23). The role on HIF-1α has been reported in cancers of cervix, colon, lungs, and skin (32); levels of phosphorylated 4E-BP1 and phosphorylated p70S6K proteins are reduced in cervical cancer and liver cancer cells (23). Thus, although the effect of silibinin on the mTOR pathway has been reported in various cancer types, the suppression of eIF4E and RPS6 mediated by silibinin in ovarian CCC lines has not been reported.

In this study, HIF-1 suppression required higher doses of silibinin in ovarian CCC than in serous carcinoma (data not shown). Even at a high dose, silibinin may be used in combination with current chemotherapy and molecular-targeted therapies. Previous in vitro studies on ovarian cancer reported that co-administration of paclitaxel with silibinin promoted apoptosis and reduced invasion; however, it targeted serous carcinoma cell lines (32, 33). Since silibinin can significantly mitigate the adverse effects compared to the current anti-cancer drugs, its long-term application may significantly contribute to the improved quality of life in patients with CCC. In the near future, we intend to conduct an in vivo experimental study on ovarian CCC to determine the appropriate silibinin concentration in combination with the existing chemotherapy regimen to achieve maximal beneficial effect. The effect of silibinin on HIF-1 degradation also remains to be investigated.

HIF-1 is an essential molecule that plays a crucial role in the maintenance of homeostasis in the body. Hence, for the clinical application of silibinin in anti-cancer therapy of ovarian CCC, an appropriate drug delivery system that does not affect cellular homeostasis needs to be established. Our study may contribute remarkably to develop novel treatment strategies for treating CCC, which has a high incidence in the Japanese population, low sensitivity to anti-cancer agents, and poor prognosis. Although the effects of silibinin on HIF-1 activity were not investigated in this study, and our results remain to be validated in future studies, we believe that silibinin is a potential candidate for use in combination therapy and postoperative chemotherapy to cure ovarian CCC.

Acknowledgements

Some analyses were performed by intégrale Co., Ltd. (Tokushima, Japan), and Macrophi Inc. (Kagawa, Japan), and some were performed and supported by Support Centre for Medical Research and Education, Tokai University. This study was supported in part by 2017 Tokai University School of Medicine Research Aid. We would like to thank Editage (www.editage.com) for English language editing.

Footnotes

  • Authors’ Contributions

    MM (Mariko Miyazawa) and MM (Masaki Miyazawa) performed molecular biological experiments, analyzed and evaluated the data. MM (Mariko Miyazawa) drafted the manuscript, MY designed and supervised the experiments, assisted with the writing of the manuscript. NO and TK interpreted the data and contributed advice about clinicopathological point of view. MY, TH, MM (Mikio Mikami) and HI interpreted the data an contributed advice in terms of treatment in obstetrics and gynecology. All Authors read and approved the final manuscript.

  • Conflicts of Interest

    The Authors declare no conflicts of interest.

  • Received October 19, 2020.
  • Revision received November 9, 2020.
  • Accepted November 13, 2020.
  • Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Coburn S,
    2. Bray F,
    3. Sherman ME and
    4. Trabert B
    : International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer 140(11): 2451-2460, 2017. PMID: 28257597. DOI: 10.1002/ijc.30676.
    OpenUrlCrossRef
  2. ↵
    1. Torre LA,
    2. Trabert B,
    3. DeSantis CE,
    4. Miller KD,
    5. Samimi G,
    6. Runowicz CD,
    7. Gaudet MM,
    8. Jemal A and
    9. Siegel RL
    : Ovarian cancer statistics, 2018. CA: CA Cancer J Clin 68(4): 284-296, 2018. PMID: 29809280. DOI: 10.3322/caac.21456
    OpenUrlCrossRefPubMed
  3. ↵
    1. Tew WP,
    2. Sill MW,
    3. Walker JL,
    4. Secord AA,
    5. Bonebrake AJ,
    6. Schilder JM,
    7. Stuckey A,
    8. Rice L,
    9. Tewari KS and
    10. Aghajanian CA
    : Randomized phase ii trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An nrg oncology/gynecologic oncology group study. Gynecol Oncol 151(2): 257-263, 2018. PMID: 30177462. DOI: 10.1016/j.ygyno.2018.08.027
    OpenUrlCrossRefPubMed
  4. ↵
    1. Okamoto A,
    2. Sugiyama T,
    3. Hamano T,
    4. Kim JW,
    5. Kim BG,
    6. Enomoto T,
    7. Aoki D,
    8. Terao, Y,
    9. Suzuki N,
    10. Mikami M
    : Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study. J Clin Oncol 32(15): 5507-5507, 2014. DOI: 10.1200/jco.2014.32.15_suppl.550
    OpenUrlCrossRef
  5. ↵
    1. Ledermann J,
    2. Harter P,
    3. Gourley C,
    4. Friedlander M,
    5. Vergote I,
    6. Rustin G,
    7. Scott C,
    8. Meier W,
    9. Shapira-Frommer R,
    10. Safra T,
    11. Matei D,
    12. Macpherson E,
    13. Watkins C,
    14. Carmichael J and
    15. Matulonis U
    : Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15): 1382-1392, 2012. PMID: 22452356. DOI: 10.1056/NEJMoa1105535
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hamanishi J,
    2. Mandai M and
    3. Konishi I
    : Immune checkpoint inhibition in ovarian cancer. Int Immunol 28(7): 339-348, 2016. PMID: 27055470. DOI: 10.1093/intimm/dxw020
    OpenUrlCrossRefPubMed
  7. ↵
    1. Semenza GL and
    2. Wang GL
    : A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12(12): 5447-5454, 1992. PMID: 1448077. DOI: 10.1128/mcb.12.12.5447
    OpenUrlAbstract/FREE Full Text
    1. Semenza GL,
    2. Nejfelt MK,
    3. Chi SM and
    4. Antonarakis SE
    : Hypoxia-inducible nuclear factors bind to an enhancer element located 3’ to the human erythropoietin gene. Proc Natl Acad Sci USA 88(13): 5680-5684, 1991. PMID: 2062846. DOI: 10.1073/pnas.88.13.5680
    OpenUrlAbstract/FREE Full Text
    1. Wang GL,
    2. Jiang BH,
    3. Rue EA and
    4. Semenza GL
    : Hypoxia-inducible factor 1 is a basic-helix-loop-helix-pas heterodimer regulated by cellular o2 tension. Proc Natl Acad Sci USA 92(12): 5510-5514, 1995. PMID: 7539918. DOI: 10.1073/pnas.92.12.5510
    OpenUrlAbstract/FREE Full Text
    1. Hirota K
    : Hypoxia-inducible factor 1, a master transcription factor of cellular hypoxic gene expression. J Anesth 16(2): 150-159, 2002. PMID: 14517667. DOI: 10.1007/s005400200011
    OpenUrlCrossRefPubMed
    1. Semenza GL
    : Hypoxia-inducible factor 1 (hif-1) pathway. Sci STKE 2007(407): cm8, 2007. PMID: 17925579. DOI: 10.1126/stke.4072007cm8
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Semenza GL
    : Targeting hif-1 for cancer therapy. Nat Rev Cancer 3(10): 721-732, 2003. PMID: 13130303. DOI: 10.1038/nrc1187
    OpenUrlCrossRefPubMed
  9. ↵
    1. Motzer RJ,
    2. Escudier B,
    3. Oudard S,
    4. Hutson TE,
    5. Porta C,
    6. Bracarda S,
    7. Grünwald V,
    8. Thompson JA,
    9. Figlin RA and
    10. Hollaender N
    : Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116(18): 4256-4265, 2010. PMID: 20549832. DOI: 10.1002/cncr.25219
    OpenUrlCrossRefPubMed
  10. ↵
    1. Huijts CM,
    2. Werter IM,
    3. Lougheed SM,
    4. Goedegebuure RS,
    5. van Herpen CM,
    6. Hamberg P,
    7. Tascilar M,
    8. Haanen JB,
    9. Verheul HM and
    10. de Gruijl TD
    : Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 68(2): 319-329, 2019. PMID: 30413837. DOI: 10.1007/s00262-018-2248-3
    OpenUrlCrossRefPubMed
  11. ↵
    1. Faggiano A,
    2. Malandrino P,
    3. Modica R,
    4. Agrimi D,
    5. Aversano M,
    6. Bassi V,
    7. Giordano EA,
    8. Guarnotta V,
    9. Logoluso FA and
    10. Messina E
    : Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: A comprehensive review of literature. The Oncologist 21(7): 875, 2016. PMID: 27053503. DOI: 10.1634/theoncologist.2015-0420
    OpenUrlAbstract/FREE Full Text
    1. Panzuto F,
    2. Rinzivillo M,
    3. Spada F,
    4. Antonuzzo L,
    5. Ibrahim T,
    6. Campana D,
    7. Fazio N and
    8. Delle Fave G
    : Everolimus in pancreatic neuroendocrine carcinomas g3. Pancreas 46(3): 302-305, 2017. PMID: 28099254. DOI: 10.1097/MPA.0000000000000762
    OpenUrlCrossRef
  12. ↵
    1. Yoo C,
    2. Cho H,
    3. Song MJ,
    4. Hong S-M,
    5. Kim K-p,
    6. Chang H-M,
    7. Chae H,
    8. Kim TW,
    9. Hong YS and
    10. Ryu M-H
    : Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemother Pharmacol 79(1): 139-146, 2017. PMID: 27942928. DOI: 10.1007/s00280-016-3215-3.
    OpenUrlCrossRef
  13. ↵
    1. André F,
    2. Hurvitz S,
    3. Fasolo A,
    4. Tseng L-M,
    5. Jerusalem G,
    6. Wilks S,
    7. O’Regan R,
    8. Isaacs C,
    9. Toi M and
    10. Burris HA
    : Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2–overexpressing metastatic breast cancers: Combined exploratory biomarker analysis from bolero-1 and bolero-3. J Clin Oncol 34(18): 2115-2124, 2016. PMID: 27091708. DOI: 10.1200/JCO.2015.63.9161
    OpenUrlAbstract/FREE Full Text
    1. Moynahan ME,
    2. Chen D,
    3. He W,
    4. Sung P,
    5. Samoila A,
    6. You D,
    7. Bhatt T,
    8. Patel P,
    9. Ringeisen F and
    10. Hortobagyi GN
    : Correlation between pik3ca mutations in cell-free DNA and everolimus efficacy in hr+, her2− advanced breast cancer: Results from bolero-2. Br J Cancer 116(6): 726-730, 2017. PMID: 28183140. DOI: 10.1038/bjc.2017.25
    OpenUrlCrossRefPubMed
    1. Jerusalem G,
    2. de Boer RH,
    3. Hurvitz S,
    4. Yardley DA,
    5. Kovalenko E,
    6. Ejlertsen B,
    7. Blau S,
    8. Özgüroğlu M,
    9. Landherr L and
    10. Ewertz M
    : Everolimus plus exemestane vs. everolimus or capecitabine monotherapy for estrogen receptor–positive, her2-negative advanced breast cancer: The bolero-6 randomized clinical trial. JAMA Oncol 4(10): 1367-1374, 2018. PMID: 29862411. DOI: 10.1001/jamaoncol.2018.2262
    OpenUrlCrossRef
  14. ↵
    1. O’Shaughnessy J,
    2. Beck JT and
    3. Royce M
    : Everolimus-based combination therapies for hr+, her2− metastatic breast cancer. Cancer Treat Rev 69: 204-214, 2018. PMID: 30092555. DOI: 10.1016/j.ctrv.2018.07.013
    OpenUrlCrossRef
  15. ↵
    1. Colon-Otero G,
    2. Weroha SJ,
    3. Foster NR,
    4. Haluska P,
    5. Hou X,
    6. Wahner-Hendrickson AE,
    7. Jatoi A,
    8. Block MS,
    9. Dinh TA and
    10. Robertson MW
    : Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecol Oncol 146(1): 64-68, 2017. PMID: 28461031. DOI: 10.1016/j.ygyno.2017.04.020
    OpenUrlCrossRefPubMed
  16. ↵
    1. Garcia-Maceira P and
    2. Mateo J
    : Silibinin inhibits hypoxiainducible factor-1alpha and mtor/p70s6k/4e-bp1 signalling pathway in human cervical and hepatoma cancer cells: Implications for anticancer therapy. Oncogene 28(3): 313-324, 2009. PMID: 18978810. DOI: 10.1038/onc.2008.398
    OpenUrlCrossRefPubMed
    1. Jung HJ,
    2. Park JW,
    3. Lee JS,
    4. Lee SR,
    5. Jang BC,
    6. Suh SI,
    7. Suh MH and
    8. Baek WK
    : Silibinin inhibits expression of hif-1alpha through suppression of protein translation in prostate cancer cells. Biochem Biophys Res Commun 390(1): 71-76, 2009. PMID: 19778521. DOI: 10.1016/j.bbrc.2009.09.068
    OpenUrlCrossRefPubMed
  17. ↵
    1. Deep G,
    2. Kumar R,
    3. Nambiar DK,
    4. Jain AK,
    5. Ramteke AM,
    6. Serkova NJ,
    7. Agarwal C and
    8. Agarwal R
    : Silibinin inhibits hypoxia-induced hif-1alpha-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics. Mol Carcinog 56(3): 833-848, 2017. PMID: 27533043. DOI: 10.1002/mc.22537
    OpenUrlCrossRef
  18. ↵
    1. Siddiqui N and
    2. Sonenberg N
    : Signalling to eif4e in cancer. Biochem Soc Trans 43(5): 763-772, 2015. PMID: 26517881. DOI: 10.1042/BST20150126.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Li L,
    2. Zeng J,
    3. Gao Y and
    4. He D
    : Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs 19(2): 243-255, 2010. PMID: 20047507. DOI: 10.1517/13543780903533631
    OpenUrlCrossRefPubMed
  20. ↵
    1. Singh RP,
    2. Dhanalakshmi S,
    3. Agarwal C and
    4. Agarwal R
    : Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, akt and nf-kappab: Implications for angioprevention and antiangiogenic therapy. Oncogene 24(7): 1188-1202, 2005. PMID: 15558015. DOI: 10.1038/sj.onc.1208276
    OpenUrlCrossRefPubMed
  21. ↵
    1. Pashaei-Asl F,
    2. Pashaei-Asl R,
    3. Khodadadi K,
    4. Akbarzadeh A,
    5. Ebrahimie E and
    6. Pashaiasl M
    : Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer. Artif Cells Nanomed Biotechnol 46(7): 1483-1487, 2018. PMID: 28884602 DOI: 10.1080/21691401.2017.1374281
    OpenUrlCrossRef
  22. ↵
    1. Yang Z,
    2. Pan Q,
    3. Zhang D,
    4. Chen J,
    5. Qiu Y,
    6. Chen X,
    7. Zheng F and
    8. Lin F
    : Silibinin restores the sensitivity of cisplatin and taxol in a2780-resistant cell and reduces drug-induced hepatotoxicity. Cancer Manag Res 11: 7111-7122, 2019. PMID: 31440098. DOI: 10.2147/CMAR.S201341
    OpenUrlCrossRef
  23. ↵
    1. Cancer Genome Atlas N
    : Comprehensive molecular portraits of human breast tumours. Nature 490(7418): 61-70, 2012. PMID: 23000897. DOI: 10.1038/nature11412
    OpenUrlCrossRefPubMed
  24. ↵
    1. Tiwari P and
    2. Mishra K
    : Silibinin in cancer therapy: A promising prospect. Cancer Res Front 1(3): 303-318, 2015. DOI: 10.17980/2015.303
    OpenUrlCrossRef
  25. ↵
    1. Zhou L,
    2. Liu P,
    3. Chen B,
    4. Wang Y,
    5. Wang X,
    6. Chiriva Internati M,
    7. Wachtel MS and
    8. Frezza EE
    : Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Res 28(2a): 1119-1127, 2008. PMID: 18507063.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Furic L,
    2. Rong L,
    3. Larsson O,
    4. Koumakpayi IH,
    5. Yoshida K,
    6. Brueschke A,
    7. Petroulakis E,
    8. Robichaud N,
    9. Pollak M and
    10. Gaboury LA
    : Proc Natl Acad Sci USA 107(32): 14134-14139, 2010. PMID: 20679199. DOI: 10.1073/pnas.1005320107
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Li J,
    2. Li B,
    3. Xu WW,
    4. Chan KW,
    5. Guan XY,
    6. Qin YR,
    7. Lee NPY,
    8. Chan KT,
    9. Law S and
    10. Tsao SW
    : Role of ampk signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma. Expert Opin Ther Targets 20(1): 7-18, 2016. PMID: 26568207. DOI: 10.1517/14728222.2016.1121236
    OpenUrlCrossRef
  28. ↵
    1. Shukla SK,
    2. Dasgupta A,
    3. Mehla K,
    4. Gunda V,
    5. Vernucci E,
    6. Souchek J,
    7. Goode G,
    8. King R,
    9. Mishra A and
    10. Rai I
    : Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget 6(38): 41146-41161, 2015. PMID: 26510913. DOI: 10.18632/oncotarget.5843
    OpenUrlCrossRef
  29. ↵
    1. Bjornsti M-A and
    2. Houghton PJ
    : Lost in translation: Dysregulation of cap-dependent translation and cancer. Cancer cell 5(6): 519-523, 2004. PMID: 15193254. DOI: 10.1016/j.ccr.2004.05.027
    OpenUrlCrossRefPubMed
  30. ↵
    1. Braunstein S,
    2. Karpisheva K,
    3. Pola C,
    4. Goldberg J,
    5. Hochman T,
    6. Yee H,
    7. Cangiarella J,
    8. Arju R,
    9. Formenti SC and
    10. Schneider RJ
    : A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 28(3): 501-512, 2007. PMID: 17996713. DOI: 10.1016/j.molcel.2007.10.019
    OpenUrlCrossRefPubMed
  31. ↵
    1. Avdulov S,
    2. Li S,
    3. Michalek V,
    4. Burrichter D,
    5. Peterson M,
    6. Perlman DM,
    7. Manivel JC,
    8. Sonenberg N,
    9. Yee D,
    10. Bitterman PB and
    11. Polunovsky VA
    : Activation of translation complex eif4f is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5(6): 553-563, 2004. PMID: 15193258. DOI: 10.1016/j.ccr.2004.05.024
    OpenUrlCrossRefPubMed
  32. ↵
    1. Hsieh AC and
    2. Ruggero D
    : Targeting eukaryotic translation initiation factor 4e (eif4e) in cancer. Clin Cancer Res 16(20): 4914-4920, 2010. PMID: 20702611. DOI: 10.1158/1078-0432.CCR-10-0433
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Sekiyama N,
    2. Arthanari H,
    3. Papadopoulos E,
    4. Rodriguez-Mias RA,
    5. Wagner G and
    6. Leger-Abraham M
    : Molecular mechanism of the dual activity of 4egi-1: Dissociating eif4g from eif4e but stabilizing the binding of unphosphorylated 4e-bp1. Proc Natl Acad Sci USA 112(30): E4036-4045, 2015. PMID: 26170285. DOI: 10.1073/pnas.1512118112
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Cancer Genome Atlas Network
    : Comprehensive molecular portraits of human breast tumours. Nature 490(7418): 61-70, 2012. PMID: 23000897. DOI: 10.1038/nature11412
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (12)
Anticancer Research
Vol. 40, Issue 12
December 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
15 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration
MARIKO MIYAZAWA, MASANORI YASUDA, MASAKI MIYAZAWA, NAOKI OGANE, TOMOMI KATOH, MITSUTAKE YANO, TAKESHI HIRASAWA, MIKIO MIKAMI, HITOSHI ISHIMOTO
Anticancer Research Dec 2020, 40 (12) 6791-6798; DOI: 10.21873/anticanres.14702

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration
MARIKO MIYAZAWA, MASANORI YASUDA, MASAKI MIYAZAWA, NAOKI OGANE, TOMOMI KATOH, MITSUTAKE YANO, TAKESHI HIRASAWA, MIKIO MIKAMI, HITOSHI ISHIMOTO
Anticancer Research Dec 2020, 40 (12) 6791-6798; DOI: 10.21873/anticanres.14702
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma
  • Google Scholar

More in this TOC Section

  • TIG1 Inhibits the mTOR Signaling Pathway in Malignant Melanoma Through the VAC14 Protein
  • Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells
  • Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes
Show more Experimental Studies

Similar Articles

Keywords

  • HIF-1α
  • silibinin
  • eIF4E
  • RPS6
  • ovarian clear-cell carcinoma
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire